Market revenue in 2023 | USD 24.9 million |
Market revenue in 2030 | USD 42.2 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.34% in 2023. Horizon Databook has segmented the India cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
India is emerging as one of the lucrative markets for bioanalytical testing across the globe. This can be attributed to low costs, the availability of industry experts, and the presence of WHO-cGMP-compliant facilities.
Due to a substantial population size, elevated birth rates, and the prevalence of consanguineous marriages in several communities, India experiences a high incidence of genetic disorders. It is estimated that each year, approximately 495,000 infants are born with congenital malformations; 390,000 with G6PD deficiency; 21,400 with Down syndrome; 9,000 with betathalassemia; 5,200 with sickle cell disease; and 9,760 with amino acid disorders in the country.
The burden of genetic disorders is relatively high in the country, which is expected to boost the demand for diagnostic tests. Thus, the market for cell and gene therapy bioanalytical testing services is anticipated to register significant growth in India.
Horizon Databook provides a detailed overview of country-level data and insights on the India cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into India cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account